gip/glp-1 receptor agonist Frontiers Alimentary Pharmacology & Therapeutics |

In animal studies, GLP1-agonists were associated with reduced fetal weight and/or growth, delayed ossification and skeletal variants, usually associated with a reduction in maternal weight gain and decreased food consumption

Involving multiple organs, these abnormalities collectively drive the clinical manifestation of the disease (i.e

Even if, in the first couple years of Mounjaro and Wegovy both being approved for the weight loss indication, the impact from just those taking it who can afford it/have the insurance for it can be significant

We go beyond the prescription to help you build a foundation of healthy habits

Although these results are highly promising, long-term data including primary CV prevention populations and utilizing other SGLT2-I will be needed to fully assess the CV outcomes with this class of medications

Study limitations As the data came from Reddit users, who tend to be younger, primarily male and mostly based in the U.S., it may not represent everyone taking these medications, the researchers noted